文献速递胸部肿瘤

恩沙替尼治疗ROS1阳性NSCLC:安全但疗效有限

Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study.
PubMed 文献 · J Thorac Oncol · 2021-07-12

这项单臂多中心2期探索性研究(NCT03608007)纳入59例既往化疗线数≤1的ROS1阳性NSCLC患者,接受恩沙替尼225 mg每日一次口服,主要终点为研究者按RECIST 1.1评估的客观缓解率。结果显示客观缓解率27.0%(95%CI 13.8-44.1),中位无进展生存期4.6个月(95%CI 4.0-6.4),≥3级治疗相关不良事件发生率25.4%,结论为疗效中等、安全性可接受。

要点

  • 恩沙替尼225 mg每日一次在ROS1阳性NSCLC中客观缓解率27.0%,中位PFS 4.6个月。
  • 4例脑转移患者中3例(75.0%)达颅内疾病控制,但样本量小需谨慎解读。
  • 最常见治疗相关不良事件为皮疹和肝酶异常,多为1-2级,≥3级发生率25.4%。

核心结论

  • 恩沙替尼在ROS1阳性NSCLC中疗效中等,安全性可接受。

研究设计与样本

  • 2期、单臂、多中心探索性研究(NCT03608007),2018年6月至2019年7月在中国23个中心共入组59例ROS1阳性NSCLC患者。
  • 入组患者既往化疗线数≤1,接受恩沙替尼225 mg每日一次口服。
  • 主要终点为研究者按RECIST 1.1评估的客观缓解率。

主要发现

  • 中位随访19.8个月(范围0.8-22.5),客观缓解率27.0%(95%CI 13.8-44.1),含10例部分缓解。
  • 中位缓解持续时间4.8个月(95%CI 1.8-10.8),中位无进展生存期4.6个月(95%CI 4.0-6.4)。
  • 中位总生存期不可估计(95%CI 14.9-不可估计)。
  • 4例脑转移患者中3例达颅内疾病控制(75.0%,95%CI 19.4-99.4)。

关键数值与推荐

  • 客观缓解率27.0%(95%CI 13.8-44.1),部分缓解10例。
  • 中位缓解持续时间4.8个月(95%CI 1.8-10.8),中位无进展生存期4.6个月(95%CI 4.0-6.4)。
  • ≥3级治疗相关不良事件发生率25.4%,最常见为皮疹和肝酶异常,多为1-2级。

临床怎么用

  • 恩沙替尼可作为ROS1阳性NSCLC化疗后或一线治疗的可选方案之一,但缓解率与PFS获益有限。
  • 用药期间需重点监测皮疹和肝酶异常,必要时调整剂量并对症处理。

局限性

  • 单臂设计无对照,样本量59例较小,结论需随机对照研究进一步验证。
  • 脑转移亚组仅4例,颅内疗效数据解释受限。
  • 中位总生存期不可估计,长期生存获益尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Some ALK inhibitors with good inhibition of ROS1 in preclinical studies have been reported to be possibly beneficial in ROS1-positive NSCLC. In this work, we studied the efficacy and safety of ensartinib in the treatment of patients with ROS1-positive NSCLC. METHODS: The exploratory study was a phase 2, single-arm, multicenter design (NCT03608007). Patients with ROS1-positive NSCLC with a previous chemotherapy line number of less than or equal to 1 who received ensartinib at the dose of 225 mg once daily were enrolled. The primary end point was objective response rate evaluated by an investigator per Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: From June 2018 to July 2019, a total of 59 patients were enrolled at 23 centers in the People's Republic of China. At the time of data cutoff, the median follow-up was 19.8 months (range: 0.8-22.5). The median objective response rate was 27.0 % (95 % confidence interval [CI]: 13.8-44.1) with 10 partial responses. Median duration of response was 4.8 months (95 % CI: 1.8-10.8). The median progression-free survival was 4.6 months (95 % CI: 4.0-6.4). The median overall survival was not estimable (95 % CI: 14.9-not estimable). Of four patients with brain metastases, intracranial disease control was reported in three (75.0 %, 95 % CI: 19.4-99.4). The most common treatment-related adverse events (TRAEs) were rash and liver enzyme abnormalities, with good prognosis after adjustment for dosage and concomitant medication. Most of the TRAEs were of grades 1 to 2, and incidence of grade greater than or equal to 3 TRAEs was 25.4 %. CONCLUSIONS: Ensartinib had a modest efficacy in patients with ROS1-positive NSCLC with an acceptable safety profile.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ai X, Wang Q, Cheng Y, et al. Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study. J Thorac Oncol. 2021. PMID: 34265433. doi:10.1016/j.jtho.2021.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。